Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 3,631Xls
2D Structure
Also known as: Sndx-5613, 2169919-21-3, Lz0m43nnf2, Sndx5613, Sndx-5613 free base, N-ethyl-2-[4-[7-[[4-(ethylsulfonylamino)cyclohexyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-5-fluoro-n-propan-2-ylbenzamide
Molecular Formula
C32H47FN6O4S
Molecular Weight
630.8  g/mol
InChI Key
FRVSRBKUQZKTOW-UHFFFAOYSA-N
FDA UNII
LZ0M43NNF2

Revumenib is an orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, revumenib targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-ethyl-2-[4-[7-[[4-(ethylsulfonylamino)cyclohexyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-5-fluoro-N-propan-2-ylbenzamide
2.1.2 InChI
InChI=1S/C32H47FN6O4S/c1-5-39(23(3)4)31(40)27-17-25(33)9-12-28(27)43-29-18-34-22-35-30(29)38-20-32(21-38)13-15-37(16-14-32)19-24-7-10-26(11-8-24)36-44(41,42)6-2/h9,12,17-18,22-24,26,36H,5-8,10-11,13-16,19-21H2,1-4H3
2.1.3 InChI Key
FRVSRBKUQZKTOW-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCN(C(C)C)C(=O)C1=C(C=CC(=C1)F)OC2=CN=CN=C2N3CC4(C3)CCN(CC4)CC5CCC(CC5)NS(=O)(=O)CC
2.2 Other Identifiers
2.2.1 UNII
LZ0M43NNF2
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Sndx-5613

2. 2169919-21-3

3. Lz0m43nnf2

4. Sndx5613

5. Sndx-5613 Free Base

6. N-ethyl-2-[4-[7-[[4-(ethylsulfonylamino)cyclohexyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-5-fluoro-n-propan-2-ylbenzamide

7. Sndx50613

8. Benzamide, N-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-n-(1-methylethyl)-

9. Sndx-50613

10. Revumenib [inn]

11. Unii-lz0m43nnf2

12. Sndx5613 Free Base

13. Sndx50613 Free Base

14. Chembl4650827

15. Schembl19693219

16. Schembl19693428

17. Gtpl11882

18. Sndx-50613 Free Base

19. Ex-a4343

20. Nsc825775

21. S8996

22. Nsc-825775

23. Ac-36885

24. Hy-136175

25. Cs-0120274

26. N-ethyl-2-((4-(7-(((1r,4r)-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-n-isopropylbenzamide

2.4 Create Date
2018-01-29
3 Chemical and Physical Properties
Molecular Weight 630.8 g/mol
Molecular Formula C32H47FN6O4S
XLogP34.3
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count10
Rotatable Bond Count11
Exact Mass630.33635334 g/mol
Monoisotopic Mass630.33635334 g/mol
Topological Polar Surface Area116 Ų
Heavy Atom Count44
Formal Charge0
Complexity1040
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1